Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)-Reference-Cited by-同舟云学术

Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

Published:2014-01-17 Issue:5 Volume:74 Page:859-866
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Seror Raphaèle,Theander Elke,Brun Johan G,Ramos-Casals Manel,Valim Valeria,Dörner Thomas,Bootsma Hendrika,Tzioufas Athanasios,Solans-Laqué Roser,Mandl Thomas,Gottenberg Jacques-Eric,Hachulla Eric,Sivils Kathy L,Ng Wan-Fai,Fauchais Anne-Laure,Bombardieri Stefano,Valesini Guido,Bartoloni Elena,Saraux Alain,Tomsic Matija,Sumida Takayuki,Nishiyama Susumu,Caporali Roberto,Kruize Aike A,Vollenweider Cristina,Ravaud Philippe,Vitali Claudio,Mariette Xavier,Bowman Simon J

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference19 articles.

1. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome;Seror;Ann Rheum Dis,2011

2. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome;Seror;Ann Rheum Dis,2010

3. Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index;Seror;Arthritis Care Res (Hoboken),2010

4. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab;Meiners;Ann Rheum Dis,2012

5. Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients;Vitali;Arthritis Rheum,2007

Cited by 208 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Sjögren disease syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Pathogenesis of Sjögren syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study;The Lancet;2024-08

4. Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease;RMD Open;2024-08

5. Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study;The Lancet Rheumatology;2024-08